Callum Baylis-Duffield, Vice President of Sales and Marketing for Plandaí, said, «Plandaí ultimately expects to expand USN’S purchases globally into other territories where USN operates, so it’s crucial that we move quickly to satisfy each of these purchase orders in South Africa. The good news is that with more contract manufacturers coming online with USN in South Africa, we expect more orders will flow from this agreement with USN.»
USN, a global health and nutrition supplement brand that is selling products in more than 50 countries and on four continents, was founded in South Africa 15 years ago. All of USN’s products are formulated with the backing of extensive research and scientific findings, as well as clinical trials to ensure efficacy and safety.
The exclusive agreement between Plandaí and USN will allow the sports nutrition brand to further control the input costs around production, while enhancing product efficacy by replacing the generic green tea extracts in its extensive lineup of innovative and market-leading products, with the clinically proven highly bioavailable Phytofare® catechin complex.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like «may," «will," «should," «could," «expect," «anticipate," «estimate," «believe," «intend," or «project» or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC’s website located at http://www.sec.gov.
Contact:
Andrew Beyer
Phone: 888-627-6902
Email:
investor@Plandaibiotech.com
http://finance.yahoo.com/news/plandai-biotechnology-inc-receives-first-130000356.html;_ylt=AwrC1CmBXlNVwiYAES2TmYlQ;_ylu=X3oDMTByMjB0aG5zBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzYw-
